The Janeway's Immunobiology CD-ROM, Immunobiology Interactive, is included with each book, and can be purchased separately. It contains animations and videos with voiceover narration, as well as the figures from the text for presentation purposes.

Autoimmune diseases are diverse and responsible for considerable morbidity. Their etiology remains largely unknown, and current therapy with anti-inflammatory drugs is prone to adverse effects, and rarely curative. New therapies with anti-cytokine antibodies or receptors are promising, but require frequent administration of expensive protein drugs. Gene Therapy of Autoimmune Diseases comprehensively reviews research in gene therapy for autoimmune diseases with viral or non-viral vectors. Gene therapy offers the possibility of long-term, continuous delivery of a wide variety of immunosuppressive, anti-inflammatory, or tolerance-inducing agents. Moreover, highly specific genetically modified cells can be produced. This book discusses the most promising avenues in this exciting new field.

Developing Costimulatory Molecules for Immunotherapy of Diseases highlights the novel concept of reverse costimulation and how it can be effectively exploited to develop immunotherapy using either humanized antibodies against CD80, CD86, and other costimulatory molecules or CD28 fusinogenic proteins in the treatment of diseases, including allergies, asthma, rheumatoid arthritis, multiple sclerosis, lupus nephritis, severe psoriasis, vulgaris tuberculosis, thopoid, transplantation therapeutic, cancer, and inflammation. The text aims to provide the latest information on the complex roles and interactions within the CD28 and B7 costimulatory families, with the hope that targeting these families will yield new therapies for the treatment of inflammation, autoimmunity, transplantation, cancer, and other infectious diseases. - Highlights the novel concept of reverse costimulation and how it can be effectively exploited to develop immunotherapy - Provides the latest information on the complex roles and interactions within the CD28 and B7 costimulatory families - Targets new therapies for the treatment of inflammation, autoimmunity, transplantation, cancer, and other infectious diseases

Branchenführende Big-Pharma-Unternehmen und erstklassige Forscher präsentieren grundlegende Konzepte und Herausforderungen bei proteinbasierten Pharmazeutika. Beinhaltet auch eine Einführung in die aus Sicht der Arzneimittelentwicklung fünf wesentlichen Anwendungsbereiche.

Regulatory T Cells in Health and Disease focuses on the mechanism by which T cells become regulatory T cells, the processes which control the number of regulatory T cells in the blood and tissue, and the ways in which regulatory T cell prevent autoimmune disease and interact with infections and cancer. - Contains contributions from leading authorities in the field of regulatory T cell biology - Informs and updates on all the latest developments in the field - Explores the processes which control the number of regulatory T cells in the blood and tissue, and the ways in which regulatory T cell prevent autoimmune disease and interact with infections and cancer

The most practical and clinical reasons for attempting to understand the immunology of infections and disease revolves around the CD137 and CD137/41BB receptor and ligand molecules. This book covers all aspects of CD137/4-1BB pathway research from microbiology, infectious disease, molecular biology, biochemistry, and genetics to immune responses and potential applications in the diagnosis and treatment of human diseases. This pathway is emerging as one of the most important targets for manipulation of immune responses for disease diagnosis and treatment. This book is written by the man who discovered the CD-137 and B7H1 molecules in 1999.